Table 2.
Relationship between cancer stem cell CSC markers and melatonin synthesis and signaling genes according to p53 status and progression of the disease.
| p53 Wild-Type | ||||||
| Gene | Early Stages | Advanced Stages | ||||
| CD44lowCD66clown (%) | CD44highCD66chighn (%) | pa | CD44lowCD66clown (%) | CD44highCD66chigh n (%) | pa | |
| NAT b | ns | 0.045 | ||||
| Low | 7 (63.6) | 17 (89.5) | 4 (40.0) | 16 (80.0) | ||
| High | 4 (36.4) | 2 (10.5) | 6 (60.0) | 4(20.0) | ||
| MT1 | ns | ns | ||||
| Low | 11 (91.7) | 19 (95.0) | 7 (77.8) | 18 (90.0) | ||
| High | 1 (8.3) | 1 (5.0) | 2 (22.2) | 2 (10) | ||
| MT2 b | ns | |||||
| Low | 8 (66.7) | 17 (85.0) | 4 (44.4) | 20 (100.0) | ||
| High | 4 (33.3) | 3 (15.0) | 5 (55.6) | 0 (0.0) | ||
| p53 Mutated | ||||||
| Gene | Early Stages | Advanced Stages | ||||
| CD44lowCD66clown (%) | CD44highCD66chighn (%) | p a | CD44lowCD66clow n (%) | CD44highCD66chighn (%) | p a | |
| NAT b | ns | ns | ||||
| Low | 6 (75.0) | 4 (80.0) | 4 (40.0) | 10 (83.3) | ||
| High | 2 (25.0) | 1 (20.0) | 6 (60.0) | 2 (16.7) | ||
| MT1 | ns | ns | ||||
| Low | 9 (100.0) | 5 (71.4) | 7 (77.8) | 11 (100.0) | ||
| High | 0 (0.0) | 2 (28.6) | 2 (22.2) | 0 (0.0) | ||
| MT2 b | ns | ns | ||||
| Low | 7 (77.8) | 6 (85.7) | 6 (66.7) | 9 (81.8) | ||
| High | 2 (22.2) | 1 (14.3) | 3 (33.3) | 2 (18.2) | ||
a Bivariate analysis: p calculated by χ2 test or Fisher’s test; b Mantel–Haenszel test: p ≤ 0.01.